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Background: Low-voltage-activated (T-type) calcium channels play a crucial role in a number of physiological
processes, including neuronal and cardiac pacemaker activity and nociception. Therefore, finding specific modulators
and/or blockers of T-type channels has become an important field of drug discovery. One characteristic of T-type
calcium channels is that they share several structural similarities with voltage-gated sodium channels (VGSCs). We
therefore hypothesized that binding sites for certain sodium channel blocking peptide toxins may be present in T-type
calcium channels.
Findings: The sodium channel blocker ProTx I tonically blocked native and transiently expressed T-type channels in the
sub- to low micro molar range with at least a ten-fold selectivity for the T-type calcium channel hCav3.1 over hCav3.3,
and more than one hundred fold selectivity over hCav3.2. Using chimeras of hCav3.1 and hCav3.3, we determined that
the domain IV region of hCav3.1 is a major determinant of toxin affinity, with a minor contribution from domain II.
Further analysis revealed several residues in a highly conserved region between T-type and sodium channels that may
correspond to toxin binding sites. Mutagenesis of several of these residues on an individual basis, however, did not
alter the blocking effects of the toxin. ProTx II on the other hand preferentially blocked hCav3.2 and significantly shifted
the steady state inactivation of this channel.
Conclusions: ProTx I blocks hCav3.1 both selectively and with high affinity. Domain IV appears to play a major role in
this selectivity with some contribution from domain II. Given the structural similarities between sodium and T-type
calcium channels and the apparent conservation in toxin binding sites, these data could provide insights into the
development and synthesis of novel T-type channel antagonists.
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Low-voltage-activated (LVA) or “T-type” calcium chan-
nels are encoded by one of three different types of Cav3
α1 subunits (Cav3.1, Cav3.2 and Cav3.3, also known as
α1G, α1H, and α1I, respectively) whose membrane top-
ology is similar to those of sodium channels [1]. They
are activated by small membrane depolarizations and
display rapid activation and inactivation kinetics [2] and
they are responsible for triggering low-threshold depo-
larizations that in turn lead to the initiation of action po-
tentials. Consequently, they are thought to be important
for regulating neuronal and cardiac pacemaker activity,
and disruption of their normal activity can contribute to
cardiac hypertrophy [3-5] and neuronal hyperexcitabilty* Correspondence: zamponi@ucalgary.ca
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unless otherwise stated.disorders such as epilepsy and pain [6-9]. Similarly, mu-
tations in Cav3.2 T-type calcium channels have been
linked to absence seizures [6,7] and up-regulation of
Cav3.2 T-type channel activity in primary afferent fibers
has been linked to the development of chronic pain
[8,9]. Indeed, depletion of Cav3.2 results in hyposensitiv-
ity to pain [10,11].
Modulators and blockers of T-type calcium channels
may be useful in elucidating the exact role of these
channels in cell signaling pathways and may be exploited
for therapeutic purposes. Identification of drugs and
molecules that selectively interact with T-type calcium
channels has, however, so far proven difficult, although
recently novel small organic scaffolds for T-type channel
inhibitors have been derived from blockers of other cal-
cium channel subtypes, such as L-type channels [12-14].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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fective blockers of voltage gated ion channels are poly-
peptide toxins. The effects of toxins on ion channels
have been extensively documented [for review see Cat-
terall et al., [15] and one toxin isolated from scorpion
venom (kurtoxin) is known to be a potent blocker of T-
type calcium channels [16]. This toxin however has been
shown to also block high-voltage activated calcium
channels [17]. More recently, two peptide toxins (ProTx
I and ProTx II), isolated from Tarantula venom, have
been shown to be potent blockers of both sodium and
calcium channels [18-20]. Given the structural similar-
ities between these two classes of ion channels, we tested
to what extent these two toxins inhibited T-type calcium
channels and identified channel structural determinants
of toxin block.
Our results reveal that ProTx II selectively blocks hu-
man Cav3.2 (hCav3.2) albeit with far less efficacy than
previous reports suggested [18]. ProTx I on the other
hand potently and preferentially blocks human Cav3.1
(hCav3.1) in the sub-micro molar range. We therefore



















































Figure 1 Tonic block of mouse neuronal or human Cav3.X [T-type] ca
1 μM application of ProTx II. For recordings from native channels, ProTx
DRG neurons, which respectively, expressed Cav3.1 and Cav3.2 channels. Sho
similar ProTx I block of native thalamic mouse T-type currents (first trace) and
mouse DRG T-type current (third trace) and recombinant human Cav3.2 (four
errors, asterisks denote statistical significance relative to either hCav3.1 [ProTx
stepping from a holding potential of −110 mV to a test potential of −20 mV.hCav3.3, as well as sequence alignment between T-type
and Nav channels and toxin interaction sites, to deter-
mine that Domain IV of hCav3.1 and, to a lesser extent
Domain II, are key toxin interaction regions.
Results and discussion
ProTx II is a preferential blocker of hCav3.2
ProTx II was originally identified as potent inhibitor of
sodium channels with fifteen to hundred- fold selectivity
for hNav1.7 versus other sodium channels [18,19]. It was
also reported to be a potent inhibitor of L-type calcium
channels and to mediate a greater degree of inhibition of
Cav3.1 versus Cav3.2 [18]. Our observations indicate
that ProTx II in fact blocks hCav3.2 more potently than
the other T-type calcium channels. The toxin blocked
endogenous Cav3.2 channels in acutely isolated mouse
DRG neurons [21] with similar potency [Figure 1].
ProTx II also dramatically shifts the steady state inacti-
vation of hCav3.2 towards more hyperpolarized poten-
tials [Table 1A] which produces additional inhibition at
typical neuronal resting membrane potentials. Interest-




































lcium channels induced by either 1 μM application of ProTx I or
I was tested on mouse thalamic neurons, ProTx II was tested on mouse
wn are representative current traces from these experiments showing
recombinant human Cav3.1 (second trace), and similar ProTx II block of
th trace) (control traces are depicted in black). Error bars reflect standard
I] or hCav3.2 [ProTx II] [*p < 0.05, **p < 0.01]. Currents were elicited by
Table 1 Summary of biophysical parameters of various T-type calcium channels in the absence or presence of A, 1 μM
ProTx II and B, 1 μM ProTx I
A
Clone Current block (%) ProTx II (1 μM) V0.5act (mV) Con V0.5act (mV) ProTx II (1 μM) Vh (mV) Con Vh (mV) ProTx II (1 μM)
hCav3.1 8.9 -51.6 -64.5** -73.7 -76.5
hCav3.2 29 -49.4 -52.1 -64.2 -76.5*
hCav3.3 8.9 -50.0 -60.7 -79 -77
B
Clone Current block (%) ProTxl (1 μM) V0.5act (mV) Con V0.5act (mV) ProTxl (1 μM) Vh (mV) Con Vh (mV) ProTxl (1 μM)
hCav3.1 wt 50 -52.3 -52.3 -74 -76
hCav3.2 wt 8 -52.6 -58.8* -64 -75*
hCav3.3 wt 26* -50.1 -50.1 -79 -75
Asterisks denote statistical significance relative to hCav3.2 [A] or hCav3.1 [B] for current block, or relative to wild type for all other parameters [*p < 0.05, **p < 0.01].
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half activation potentials of these channels in the presence
of as little as 1 μM of the toxin [Table 1A]. Together, these
data indicate that ProTx II interacts with hCav3.2 chan-
nels in a way similar to β-scorpion toxin interactions with
sodium channels [15], and that it also modulates the gat-
ing behavior of hCav3.1 and hCav3.3 channels.
ProTx I is both a potent and selective blocker of hCav3.1
ProTx I belongs to the inhibitory cysteine knot (ICK) fam-
ily of peptide toxins that are known to interact with
voltage-gated ion channels [18,22] and to be potent inhibi-
tors of voltage-gated sodium channels [18-20,23]. More
recently, several studies demonstrated that ProTx I could
also potently block the human Cav3.1 calcium channel
[18,24]. One of these studies showed that ProTx I was se-
lective for hCav3.1 over hCav3.2 and that this selectivity
may be in part attributed to the S3-S4 linker in Domain
IV of hCav3. [24]. In our hands, when applied to transi-
ently expressed hCav3 channels, ProTx I preferentially
inhibited hCav3.1 channels, with less block of hCav3.3
and only very little inhibitory effect on hCav3.2. We tested
1 μM ProTx I on endogenous Cav3.1 that comprise a large
portion of T-type current in isolated mouse thalamic neu-
rons [25], and observed inhibition that was similar to that
of hCav3.1 [Figure 1, Table 1B]. Contrary to previous find-
ings, we did not observe any significant positive shifts in
the half activation potential of hCav3.1 in the presence of
1 μM ProTx I in spite of its potent inhibitory effects, nor
was the gating of hCav3.3 channels affected [Figure 2A,C
and Table 1B]. In contrast, hCav3.2 channels underwent
shifts in both the half-activation and inactivation potential
in the presence of the toxin [Figure 2B, Table 1B].
The domain IV region of hCav3.1 is important for ProTx I
block and function of hCav3.1
We had previously constructed a series of chimeric
channels in which we had swapped various membranedomains between Cav3.1 and Cav3.3 [26]. We used a
subset of these chimeras to ascertain which of the mem-
brane domains were responsible for the differences in
ProTx I blocking effects on these two channel subtypes.
As shown in Figure 3, chimeras that contained the Do-
main IV region of hCav3.1 exhibited a degree of block
that was similar in magnitude to that of the wild type
channel, whereas constructs that contained Cav3.3 se-
quence in this domain behaved liked the wild type
Cav3.3 channels [Figure 3]. These data indicate that Do-
main IV is a major determinant of ProTx I action on T-
type calcium channels. In addition, replacing domain II
in the IGIG chimera with corresponding Cav3.3 se-
quence (IIIG) weakened the blocking effect, suggesting
that domain II may also contribute to toxin action. We
also examined the effect of the toxin on the gating be-
havior of these sets of chimeras. Most of the chimeras
did not undergo a toxin induced change in half-
activation or inactivation potential as expected from our
observation with wild type channels, although two con-
structs exhibited a minor depolarizing shift in half activa-
tion potential when the toxin was applied [Table 2]. We
note that a previous study in which ProTx I was shown to
induce a dramatic shift in half activation potential of
Cav3.1 used a cDNA derived from rat [18]. We therefore
tested ProTx I on rat Cav3.1 and although there was a
slight positive shift in activation, it did not reach signifi-
cance. We did, however, observe a small but significant
negative shift in the steady state inactivation that was con-
sistent with previous findings [18] and which curiously
contrasts with our observation with human Cav3.1 where
no significant shift was observed [Table 2].
Substitution of individual amino acid residues in the
putative toxin blocking sites do not affect ProTx I block
of hCav3.1
Given the high degree of homology between T-type cal-




































































































































Figure 2 A,B,C, ProTx I Dose response (left), steady state inactivation (middle) and current voltage relations (right) for hCav3.1,
hCav3.2 and hCav3.3, respectively. Steady state inactivation and current voltage relations were recorded prior and after application of 1 μM
ProTx I. Ensemble dose response curves for tonic channel inhibition by ProTx I were fitted via the Hill equation and IC50’s for hCav3.1, 3.2 and 3.3
were 0.64, 94.6 and 5.4 μM respectively. Insets are representative current traces of each calcium channel before and after (red trace) application of
1 μM ProTx I (Note that the trace for hCav3.1 is the same as in figure 1). All other data were fitted with the Boltzmann equation and are from
multiple paired experiments [n = 5-6 per channel]. Note the negative shift in both the half activation and steady state inactivation potential in the
presence of 1 μM ProTx I for hCav3.2 despite this concentration having minimal effect on tonic block.
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of these channels to determine if there were any sites
that were unique to hCav3.1 that might be involved in
toxin block, taking into consideration the loci of amino
acid residues that are known to be involved in toxin
block of voltage-gated sodium channels [27-29]. Our
alignment results (Figure 4A) yielded nine candidate
residues, two in Domain II of hCav3.1 and seven in
Domain IV. To determine whether these residues may
be involved in ProTx I block of hCav3.1, we replaced all
nine residues with corresponding residues in Cav3.3, and
then assessed ProTx I block of these mutant channels.
As shown in Figure 4B and Table 3, three of the amino
acid residues resulted in non-functional channels. Sur-
face biotinylation experiments revealed that these mu-
tant channels were trafficked appropriately to the cellsurface (data not shown), indicating that their inability
to support whole cell currents was not due to an ab-
sence of expression. Instead, since these substitutions
are in the region thought to be involved in inactivation,
it is likely that these substitutions disrupted this mech-
anism. Of the remaining mutations, none resulted in a
significant decrease in ProTx I block. Two of the muta-
tions V1618A and Q1631K both displayed a significant
negative shift in their half inactivation potential com-
pared to wild type channels. In addition, the V1618A
mutant also showed a significant positive shift in half ac-
tivation potential compared to wild type [Table 3A].
These data indicate that although individual candidate
amino acid residues cannot account for the blocking ef-
fects of this toxin, these residues do play a minor role in






































Figure 3 Tonic block of hCav3.1-hCav3.3chimeras by 1 μM
application of ProTx I. Chimera nomenclature is as follows: hCav3.1
sequence in domains I-IV is denoted by “G”, hCav3.3 sequence is
denoted by “I”. Note that block of hCav3.1 and Chimeras that contain
Domain IV of hCav3.1 are similar (see top dashed line). The bottom
slashed line represents percent tonic block of 1 μM ProTx I of wild type
hCav3.3. [n = 5-6 per channel, at 1 μM]. Error bars reflect standard
errors, asterisks denote statistical significance relative to hCav3.1 [*p <
0.05, **p < 0.01]. Currents were elicited by stepping from a holding
potential of −110 mV to a test potential of −20 mV.
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Previous studies have shown that the tarantula venom
peptides ProTx I and ProTx II inhibit voltage-gated so-
dium channels by shifting their voltage dependence of
activation to more positive potentials [18,20]. Our re-
sults show that ProTx I preferentially blocked hCav3.1 at
sub-micro molar concentrations, but we did not observe
any shift in half activation potential. Contrary to previ-
ous findings [18], ProTx II appeared to preferentially
block hCav3.2. This toxin block caused a significant
negative shift in half inactivation voltage of hCav3.2, but
in contrast with previous studies on sodium and calcium
channels, no significant change in half activation poten-
tial [18,30,31]. The apparent differences between some
of our results and those of previous studies, may be in
part be due to the different expression systems,Table 2 Summary of biophysical parameters of human Cav3.1,
presence of 1 μM ProTx I
Chimera Current block (%) ProTx I (1 μM) V0.5act (mV) Con V







rCav3.1 wt 60 -57.6
Asterisks denote statistical significance relative to hCav3.1 for current block. The harecording methods and clones used. In previous studies,
HEK cells and Xenopus oocytes were used to express rat
Cav3 channels and toxin effect and channel kinetics
were measured on tail currents as an indicator of po-
tency. We attempted to address this discrepancy by
using ProTx I on a rat Cav3.1 clone available to us and
although our results showed a small positive shift in the
voltage-dependence of activation [Table 2], it did not
reach significance. Further experiments will need to be
conducted to determine the precise biophysical interac-
tions of this toxin with T-type calcium channels, and
how toxin actions are affected by different experimental
conditions.
Conclusions
Our data show that ProTx I and ProTx II potently and
preferentially block hCav3.1 and hCav3.2 respectively.
These two toxins block and modify T-type calcium
channels using mechanisms similar to their interaction
with sodium channels [18,20]. Their effect on the voltage
dependence of inactivation is reminiscent of β-scorpion
toxin interactions with sodium channels [15]. Overall,
our data suggest that both ProTx I and ProTx II may be
useful towards exploring the gating mechanisms of T-
type calcium channels. Finally, the apparent similarities
in the toxin binding sites between Nav and Cav channels
may provide an insight into the synthesis of more potent




Human Cav3.2 cDNA was kindly provided by Dr. Terrance
Snutch (University of British Columbia, Vancouver,
Canada). Human Cav3.3 was obtained from Dr. Arnaud
Monteil (CNRS Montpellier, France), human Cav3.1 was
described previously by our laboratory [32] and human
Cav3.1 and Cav3.3 chimeras were also described previ-
ously [26].rat Cav3.1 and hCav3.1-hCav3.3 chimeras in the absence or
0.5act (mV) ProTx I (1 μM) Vh (mV) Con Vh (mV) ProTx I (1 μM)
-52.3 -74 -76
-44.5 -75.3 -77.5
-49.0 # -76.1 -75.9
-33.5 # -73.2 -73.2
-34.6 # -68.9 -69.3
-41.0 -74.0 -73.7
-38.8 -72.5 -73.7
-54.2 -75.1 -80.9 #


























































































Figure 4 A Sequence alignment of the human sodium channel 1.7 (hNav1.7) versus the three T-type calcium channels (sites targeted
with mutagenesis highlighted in red). B, Tonic block of human Cav3.1 and Cav3.1 mutants induced by 1 μM application of ProTx I. Domain II
mutations are denoted in blue, Domain IV mutations are shown in red [n = 5-6 per channel, at 1 μM]. Note that the last three mutations in
Domain IV produced a non-functional channel (NF). Error bars reflect standard errors. Currents were elicited by stepping from a holding potential
of −110 mV to a test potential of −20 mV.
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Unless stated otherwise, chemicals were purchased from
Sigma (St. Louis, MO). Both ProTx I and ProTx II were
purchased from Alomone Labs (Jerusalem, Israel) and
were dissolved in external recording solution at the
stock concentration of 1 mM. All subsequent dilutions
were also made in external recording solution.Table 3 A, Summary of biophysical parameters of hCav3.1 an
biophysical parameters of hCav3.1 domain II mutants in the
A
DOM IV mutant IC50 Tonic ProTx I (μM) V0.5act (mV) Con
hCav3.1 wt 0.64 -52.3
hCav3.1 V1618A 0.66 -51.5
hCav3.1 Q1631K 0.92 -53.2
hCav3.1 S1659A 1.29 -53.1
hCav3.1 M1696V 1.27 -51.5
B
DOM II mutant Current block (%) ProTx l (1 μM) V0.5act (mV) Con
Q826A 40 -53.6
G827D 38 -52.4
QG826-7 AD 40 -51
Asterisks denote statistical significance relative to wild type hCav3.1 [*p < 0.05].tsA-201 cell culture and transfection
Human embryonic kidney tsA-201 cells were cultured
and transfected using the calcium phosphate method as
described previously [33]. Briefly, 6 μg of T-type calcium
channel Cav3.1, Cav3.2, and Cav3.3, α1 subunits were
transfected together with 0.5 μg Enhanced green fluores-
cent protein (EGFP) DNA (Clontech) as a marker. Cellsd hCav3.1 domain IV mutants and B, Summary of
absence or presence of 1 μM ProTx I
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trogen) and plated on glass cover slips a minimum of 3
to 4 hours before patching and kept at 37°C and 5%
CO2.
Isolation of neurons
Thalamic neurons were isolated as described previously
[34]. Briefly, thalami of adult mice were dissected out,
cut into small pieces and then digested in papain
(Worthington, LS003126) containing culture media.
After digestion, the tissue was washed and triturated for
neuron dissociation. Thalamic neurons were then seeded
at low density onto coverslips pretreated with poly-d-
lysine (Sigma, P7280). Dorsal Root Ganglia (DRG) neu-
rons were isolated as described previously [21]. Briefly,
DRG from adult mice were removed and placed in Ca2+
and Mg2+-free Hank’s Balanced Salt Solution, containing
(in mM): 140 NaCl, 5.3 KCl, 0.4 KH2PO4, 0.3 Na2HPO4,
6 D-glucose, 10 HEPES, and 2 mg/mL collagenase (Type
I, Worthington, Lakewood, New Jersey), and 200 units
of DNaseI (Worthington, Lakewood, New Jersey). Gan-
glia were then incubated for 45 min at 37°C and subse-
quently placed in media supplemented with 10% fetal
bovine serum to stop digestion. Cells were then dis-
persed with fire polished Pasteur pipettes and plated on
glass coverslips coated with 100 μg/mL poly-L-lysine.
Electrophysiology
Whole-cell voltage-clamp recordings on tsA- 201 cells
were performed at room temperature 2 to 3 days after
transfection. Whole-cell voltage-clamp recordings on
Neuronal cells were performed at room temperature, the
following day after isolation. The external recording so-
lution for all calcium channel recordings contained (in
mM): 114 CsCl, 20 BaCl2, 1 MgCl2, 10 HEPES, 10 Glu-
cose, adjusted to pH 7.4 with CsOH. For voltage-clamp
recordings on neuronal cells, 5 μM CdCl2 was also
added to the external solution to inhibit high voltage ac-
tivated calcium channels. For all recordings, the internal
patch pipette solution contained [in mM]: 108 CsMeSO4,
2 MgCl2, 11 EGTA, 10 HEPES adjusted to pH 7.3 with
CsOH. The internal solution was supplemented with
0.6 mM GTP and 2 mM ATP, which were added directly
to the internal solution immediately before use. Liquid
junction potentials for the above solutions were left uncor-
rected. Recordings were digitized at 5 kHz and low-pass
filtered at 1 kHz.
Toxins were prepared daily in external solution and
applied locally to cells with the use of a custom built
gravity driven micro-perfusion system that exchanges so-
lution in approximately one second [35]. Currents were
elicited from a holding potential of −110 mV and were
measured by conventional whole-cell patch clamp using
an Axopatch 200B amplifier in combination with Clampex9.2 software (Molecular Devices, Sunnyvale, CA). After es-
tablishment of the whole cell configuration, cellular cap-
acitance was minimized using the analog compensation
available on the amplifier. Series resistance was <10 MΩ
and was compensated >85% in all experiments. Data were
filtered at 1 kHz (8-pole Bessel) and digitized at 10 kHz
with a Digidata 1320 interface (Molecular Devices). In
addition to collecting the raw data, an online leak-
subtraction protocol was used in which four pulses of op-
posite polarity and one-quarter amplitude were applied
immediately before the test protocol. For current–voltage
relation studies, the membrane potential was held at
−100 mV and cells were depolarized from −80 to 20 mV
in 10 mV increments. For steady-state inactivation studies,
the membrane potential was depolarized by test pulses to
−20 mV after 3.6-s conditioning pre-pulses ranging from
−110 to −20 mV. The current amplitude obtained from
each test pulse was then normalized to that observed at a
holding potential of −110 mV.Data analysis and statistics
Data were analyzed using Clampfit 9.2 (Molecular De-
vices). Preparation of figures and curve fitting was car-
ried out with Origin 7.5 software (Northampton, MA,
USA). Current–voltage relationships were fitted with the
modified Boltzmann equation: I = (Gmax*(Vm-Erev))/(1 +
exp((V0.5act-Vm)/ka)), where Vm is the test potential,
V0.5act is the half-activation potential, Erev is the reversal
potential, Gmax is the maximum slope conductance, and
ka reflects the slope of the activation curve. Data from
concentration-dependence studies were fitted with the
equation y = A2 + (A1-A2)/(1 + ([C]/IC50)
P) where A1 is
initial current amplitude and A2 is the current ampli-
tude at saturating drug concentrations, [C] is the drug
concentration and P is the Hill coefficient. Statistical sig-
nificance was determined by paired or unpaired Stu-
dent’s t-Tests and one-way or repeated measures
ANOVA followed by Tukey’s multiple comparison tests.
Significant values were set as indicated in the text and
figure legends. All data are given as means +/− standard
errors. Steady-state inactivation curves were fitted using
the Boltzmann equation: I = 1/(1 + exp((Vm-Vh)/k)),
where Vh is the half-inactivation potential and k is the
slope factor.Ethical standards
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